suloctidil and Hyperlipidemias

Topics: ABO Blood-Group System; Alprenolol; Blood Coagulation; Blood Viscosity; Cell Adhesion; Erythrocyte Aggregation; Erythrocytes; Heart Diseases; Hemodynamics; Humans; Hyperlipidemias; Mathematics; Pentoxifylline; Rheology; Smoking; Suloctidil; Thrombosis

Two studies were carried out in patients with primary hyperlipidaemia to investigate the effect of suloctidil (200 mg 3-times daily) on serum cholesterol levels and other lipidaemic variables. The first study was a double-blind, crossover comparison of suloctidil and placebo in 23 patients. Patients were allocated at random to receive one or other treatment for 4 weeks, after a wash-out period of 4 weeks on placebo, and were then crossed over to the alternative medication for the following 4 weeks. Patients were kept on a controlled diet throughout the trial. In the second, long-term study, 28 patients were treated, after an initial washout period of 8 weeks on placebo, with suloctidil for periods of up to 1 year. As in the short-term trial, patients were maintained on a controlled diet. The results showed that suloctidil produced a statistically significant reduction in total serum cholesterol and serum triglycerides in the short-term and this reduction was maintained over the longer period of the second study. In addition, there was a concomitant and approximately proportional increase in HDL-cholesterol. Suloctidil was well tolerated and no serious side-effects were reported.

Topics: Body Weight; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans; Hyperlipidemias; Propanolamines; Random Allocation; Suloctidil; Triglycerides